Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.
Last trade$96.49
Day change-$2.75 (-2.77%)
Day range$94.92 – $101.01
Volume457,364
Market cap$6.73B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$6.73B
Price / earnings
—
Price / book
5.62×
Price / sales
—
EV / sales
—
EV / EBITDA
-35.74×
Profitability
Earnings per share
-$2.01
Return on assets
-11.06%
Return on equity
-11.38%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
29.62×
Quick ratio
29.62×
Cash ratio
6.03×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$123.86M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ORKA, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q3 FY2024 Sep 30, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$8.44M
$6.85M
$7.29M
$6.79M
$5.12M
$4.34M
$5.16M
$3.76M
Research and development
$53.7M
$43.26M
$29.15M
$27.64M
$28.99M
$24.09M
$19.93M
$25.69M
Total operating expenses
$62.14M
$50.11M
$36.43M
$34.43M
$34.11M
$28.43M
$25.09M
$29.45M
Operating income
-$62.14M
-$50.11M
-$36.43M
-$34.43M
-$34.11M
-$28.43M
-$25.09M
-$29.45M
Interest expense
$0
$0
$0
$0
$0
$0
$0
-$504K
Income before taxes
-$49.97M
-$41.21M
-$31.82M
-$29.58M
-$30.28M
-$24.57M
-$21M
-$28.62M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$49.97M
-$41.21M
-$31.82M
-$29.58M
-$30.28M
-$24.57M
-$21M
-$28.62M
Net income attributable to common shareholders
-$45.01M
-$34.87M
-$31.82M
-$24.5M
-$24.04M
-$19.33M
-$21M
-$21.94M
EBITDA
-$62.09M
-$50.06M
-$36.39M
-$34.4M
-$34.09M
-$28.41M
-$25.07M
-$29.45M
Basic earnings per share
-$0.63
-$0.55
-$0.48
-$0.44
-$0.55
-$0.46
-$0.40
-$1.46
Diluted earnings per share
-$0.63
-$0.55
-$0.48
-$0.44
-$0.55
-$0.46
-$0.40
-$1.46
Recent news
Company coverage with links to the original publishers.
Oruka Therapeutics announced it will report Week 16 data for ORKA-001 from the EVERLAST-B Phase 2b trial in moderate-to-severe plaque psoriasis on October 26, 2026. The company will host a conference call and webcast at 8:00 a.m. ET to discuss the results. Previously announced Week 28 data from the EVERLAST-A trial showed positive results with PASI 100 reaching 71.4% and PASI 90 reaching 87.3% without additional dosing after Week 4.
Revolution Medicines and Oruka Therapeutics have significantly outperformed the Magnificent Seven tech stocks this year, both more than doubling. Revolution Medicines gained FDA approval for Rasonque, a pancreatic cancer treatment with blockbuster potential ($20.8B peak revenue projected). Oruka Therapeutics is developing ORKA-001 for psoriasis with promising Phase 2 results and convenient once-yearly dosing. While Wall Street sees substantial upside (36% for RVMD, 95% for ORKA), both stocks carry significant risk due to clinical uncertainty and limited approval history.
Oruka Therapeutics reported positive Week 28 interim data from its EVERLAST-A Phase 2a trial of ORKA-001, an IL-23p19 monoclonal antibody for plaque psoriasis. The drug demonstrated deepening clinical responses with 71.4% of patients achieving PASI 100 (complete skin clearance) and 87.3% achieving PASI 90, six months after the last dose with no additional dosing beyond Week 4. The drug maintained a favorable safety profile consistent with the IL-23 class. Full 52-week data is expected in December 2026.
Oruka Therapeutics announced the appointment of Todd Edwards as Chief Commercial Officer effective August 24, 2026. Edwards brings over 25 years of commercial leadership experience in immunology and dermatology from previous roles at Arcutis Biotherapeutics, Incyte Corporation, UCB S.A., and AbbVie. The appointment reflects Oruka's commitment to building a commercial organization to advance its pipeline candidates ORKA-001 and ORKA-002 toward commercialization for chronic skin diseases.
Oruka Therapeutics' Senior Vice President of Finance Arjun Agarwal sold 9,854 shares worth approximately $687,000 in mid-June 2026, reducing his direct holdings by 36.83%. The sale occurred after the stock had already surged 450% over the previous year and two weeks before it reached nearly 700% gains. The insider sale follows positive Phase 2 clinical data for the company's monoclonal antibody therapies ORKA-001 and ORKA-002, though the company continues to operate at a net loss with quarterly losses widening to $31.8 million.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.